A miss in first quarter revenue estimates, coupled with manufacturing troubles at one of its US facilities, conspired to send Mylan (Nasdaq: MYL) shares plummeting nearly 20% on Tuesday morning in New York.
The firm reported total revenues of $2.5 billion, down 7% compared to the prior year period, and adjusted diluted earnings per share (EPS) of $0.82, down 15% over the prior year period.
The decrease in net sales, which included a 14% decline in Europe and 6% in North America, was partially offset by a 3% increase in the Rest of World segment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze